Triple-negative breast cancer (TNBC) covers 10–20% of all breast carcinomas and represents a heterogeneous category, defined by the absence of the three key breast cancer receptors: ER, PR, and HER2. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.